Atrovent Dosage/Direction for Use

The dosage should be adapted to the individual requirements and the patients should be kept under medical supervision during treatment. It is advisable not to exceed the recommended daily dose during either acute or maintenance treatment.
If therapy does not produce a significant improvement or if the patient's condition gets worse, medical advice must be sought in order to determine a new plan of treatment. The patient should be instructed that in the case of acute or rapidly worsening dyspnoea physician should be consulted immediately.
The following dosages are recommended: (20 drops=about 1 mL; 1 drop=0.0125 mg ipratropium bromide anhydrous).
Maintenance treatment: Adults (including elderly) and adolescents over 12 years of age: 2.0 mL (40 drops=0.5 mg ipratropium bromide anhydrous) 3 to 4 times daily.
Children 6-12 years: Because there is limited information in this age group, the following dose recommendation should be given under medical supervision: 1.0 mL (20 drops=0.25 mg ipratropium bromide anhydrous) 3 to 4 times daily.
Children <6 years of age: Because there is limited information in this age group the following dose recommendation should be given under medical supervision: 0.4-1.0 mL (8-20 drops=0.1-0.25 mg ipratropium bromide anhydrous) 3 to 4 times daily.
Acute attacks: Adults (including elderly) and adolescents >12 years of age: 2.0 mL (40 drops=0.5 mg ipratropium bromide anhydrous); repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician.
ATROVENT can be administered combined with an inhaled beta-agonist.
Children 6-12 years of age: Because there is limited information in this age group, the following dose recommendation should be given under medical supervision: 1.0 mL (20 drops=0.25 mg ipratropium bromide anhydrous); repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician.
ATROVENT can be administered combined with an inhaled beta-agonist.
Children <6 years of age: Because there is limited information in this age group the following dose recommendation should be given under medical supervision: 0.4-1.0 mL (8-20 drops=0.1-0.25 mg ipratropium bromide anhydrous); repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician.
ATROVENT can be administered combined with an inhaled beta-agonist.
Daily doses exceeding 2 mg ipratropium bromide anhydrous in adults and adolescents >12 years of age and 1 mg in children ≤12 years of age should be given under medical supervision.